Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.67 |
| ▸ | BRD4 | O60885 | 1/20 | 0.50 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.49 |
| ▸ | PIK3CD | O00329 | 11/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6016566 | 0.81 | LMNA (0.42) | SMN1; SMN2LMNAHSD17B10HIF1A | |
| SCHEMBL27881279 | 0.80 | LMNA (1.00) | SMN1; SMN2LMNAHSD17B10BRD4PIK3CG | |
| SCHEMBL6016517 | 0.80 | EGFR (0.42) | SMN1; SMN2LMNAHSD17B10 | |
| SCHEMBL9204579 | 0.75 | LMNA (0.66) | SMN1; SMN2LMNAHSD17B10PIK3CGCYP1A2 | |
| SCHEMBL2803764 | 0.74 | LMNA (0.53) | SMN1; SMN2LMNAHSD17B10BRD4CYP1A2 | |
| SCHEMBL6016516 | 0.73 | EGFR (0.45) | — | |
| SCHEMBL3730455 | 0.72 | LMNA (0.62) | SMN1; SMN2LMNAHSD17B10PIK3CGCYP1A2 | |
| SCHEMBL4923735 | 0.72 | PRMT1 (0.66) | SMN1; SMN2LMNAHSD17B10BRD4CYP1A2 | |
| SCHEMBL795950 | 0.69 | MKNK1 (0.68) | SMN1; SMN2LMNAHSD17B10BRD4 | |
| SCHEMBL6016359 | 0.68 | CCNB2 (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1244668-B1 | PURINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND USE THEREOF | UNIVERSITAIRE INSTELLING ANTWE (BE) | 2006-04-05 | — | — | EP | claimed |
| US-20030187261-A1 | Purine derivatives, process for their preparation and use thereof | USTAV EXPERIMANTALNI BOTANIKY AKADEMIE VED CESKE REPUBLIKY (CZ) | 2003-10-02 | — | — | US | claimed |
| US-20030187261-A1 | Purine derivatives, process for their preparation and use thereof | USTAV EXPERIMANTALNI BOTANIKY AKADEMIE VED CESKE REPUBLIKY (CZ) | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187261-A1 | Purine derivatives, process for their preparation and use thereof | DCK, DTYMK, CCNK | SMN1; SMN2 2887/4885LMNA 1866/4885HSD17B10 4662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.